CALGARY, Oct. 18, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics
Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at
the 2016 BIO Investor Forum in a session on Wednesday, October 19th, 2016 at
11:00 a.m. PT (2:00 p.m. ET). The conference takes
place on October 18th and
19th at the Westin St. Francis Hotel in San Francisco, CA.
A live audio link to the webcast session will be available at:
http://www.veracast.com/webcasts/bio/investorforum2016/38213260151.cfm.
A link to the presentation will also be available on the
company's website at:
http://www.oncolyticsbiotech.com/investor-centre/presentations/. It
is recommended that listeners log on 10 minutes in advance of a
live presentation to register and download any necessary software.
Links to the audio replays will be accessible following the
presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a
Calgary-based biotechnology
company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics' clinical program
includes a variety of later-stage, randomized human trials in
various indications using REOLYSIN®, its proprietary
formulation of the human reovirus. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks,
delays, uncertainties and other factors not under the Company's
control and which may cause actual results, performance or
achievements of the Company to be materially different from the
results, performance or expectations implied by these
forward-looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN® as a
cancer treatment, the success and timely completion of clinical
studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking
statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.